Jose Maria Vieitez

Dr. Jose Maria Vieitez

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 January 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
ALAndrea Lopez-López
Andrea Lopez-López
MRMargarita Regueiro-Abel Regueiro-Abel
Margarita Regueiro-Abel Regueiro-Abel
CJCharigan Abou Johk-Casas
Charigan Abou Johk-Casas
JVJose Maria Vieitez
Jose Maria Vieitez
JEJuliana Elices-Teja
Juliana Elices-Teja
Carlos Gonzalez-JuanateyCarlos Gonzalez-Juanatey
Carlos Gonzalez-Juanatey
Background/Objectives: Reduced-ejection-fraction heart failure (HFrEF) constitutes a challenge due to its high morbidity and mortality. The use of sacubitril/valsartan (angiotensin receptor–neprilysin inhibitors [ARNI]) and SGLT2 inhibitors (SGLT2i) represents a change in management approach with a demonstrated association with positive ventricular remodeling and a reduction in cardiovascular events. We describe the clinical and therapeutic course of patients with HFrEF in a specialized unit, comparing two consecutive periods (2011–2016 vs. 2017–2021), with emphasis on the impact of ARNI and SGLT2i upon clinical parameters and the use of devices. Methods: A retrospective, longitudinal observational study was carried out in 1363 outpatients with HFrEF, with at least two years of follow-up. Clinical characteristics, treatments, the evolution of left ventricular ejection fraction (LVEF), mortality, and the use of devices (implantable cardioverter–defibrillator [ICD], cardiac resynchronization therapy [CRT]) were evaluated. Results: A total of 1363 patients were analyzed, showing a significant therapeutic change in the 2017–2021 group with the incorporation of ARNI (40%) and SGLT2i (25%). This cohort achieved better ventricular recovery, with a significantly higher mean LVEF at one year compared to the 2011–2016 group (44.3% vs. 42.1%; p = 0.004). Regarding devices, ICD implantation rate decreased in the recent period (7.2% vs. 11.1%; p = 0.016), while CRT indication increased. Most importantly, all-cause mortality after two years fell from 9.4% to 5.9% (p = 0.023). Multivariate analysis confirmed that this survival improvement was independently associated with the study period (HR 1.57 for the earlier group) and was linked to the protective effect of contemporary pharmacological treatments. Conclusions: The systematic introduction of ARNI and SGLT2i in the treatment of HFrEF was associated with improved ventricular function, reduced need for device implantation, and lower mortality over the middle term in a real-life clinical setting.

30 July 2020 in European Heart Journal - Cardiovascular Imaging
Verified
Journal Article
Closed access
JVJose Maria Vieitez
Jose Maria Vieitez
VAVivencio Barrios Alonso
Vivencio Barrios Alonso
CFCovadonga Fernández-Gofín
Covadonga Fernández-Gofín

1 November 2020 in European Heart Journal
Verified
Journal Article
Open access
PDF file
MSM Abellas Sequeiros
M Abellas Sequeiros
AMA Garcia Martin
A Garcia Martin
AGA Gonzalez
A Gonzalez
RBR Hinojar Baydes
R Hinojar Baydes
LRLuis Miguel Rincón
Luis Miguel Rincón
CGC Fernandez Golfin
C Fernandez Golfin
Introduction: The indication of valve replacement surgery in patients with severe aortic regurgitation (AR) is mainly based on the presence of symptoms or dilatation/dysfunction of the left ventricle (LV). However, diastolic function and natriuretic peptides have not been related to adverse outcomes in these patients. The aim of this study was to evaluate the prognosis impact of different diastolic function parameters as well as type-B natriuretic peptide (BNP). Methods: Patients with moderate to severe or severe AR evaluated in the Heart Valve Clinic between 2013–2019 were evaluated. Those patients with classical indications for surgical aortic valve replacement (SAVR) at the moment of inclusion were excluded, as well as those patients with atrial fibrillation. Echocardiographic and analytical data were obtained from the medical history. End-point included cardiovascular mortality, SAVR and heart failure. Results: A total of 126 patients were included. Median age was 65.0±17.7 years. Among them, 75 (59.5%) were men, 78 (62.4%) hypertensive, 44 (35.3%) suffered from dyslipidemia and 11 (9,6%) had ischaemic cardiomyopathy. During a median follow up of 31±17 months, 24.6% of the patients reached the combined end-point (n=5 developed heart failure, n=28 underwent SAVR, and n=4 died). Among the diastolic parameters [E wave, A wave, E/A, E/e', left atrial volume and diameter, tricuspid regurgitation (TR) degree and pulmonary systolic pressure (PSP)], only TR degree and PSP were associated with a higher incidence of the combined endpoint: TR degree HR=2,08, p=0,039 and PSP HR= 1,1, p=0,007. BNP also showed prognostic impact for the combined endpoint (HR= 1,002, p=0,011). Conclusions: In patients with asymptomatic significant AR, severity of TR, PSP and BNP levels are associated with worst prognosis. However, classical echocardiographic diastolic parameters do not show prognosis impact, probably due to the limitations of such parameters to identify diastolic dysfunction and high filling pressures in this population. Our findings support the use of PSP and TR over diastolic function parameters to better stratify left valvular patient risk in clinical practice. Funding Acknowledgement: Type of funding source: None

27 January 2023 in Revista Española de Cardiología (English Edition)
Verified
Journal Article
Closed access
JVJose Maria Vieitez
Jose Maria Vieitez
FPFrancisco José Hernández Pérez
Francisco José Hernández Pérez
CMCristina Mitroi
Cristina Mitroi
SJSara Lozano Jiménez
Sara Lozano Jiménez
MBManuel Gómez Bueno
Manuel Gómez Bueno
JCJavier Segovia Cubero
Javier Segovia Cubero

27 June 2021 in Medicine - Programa de Formación Médica Continuada Acreditado
Verified
Journal Article
Closed access
JVJose Maria Vieitez
Jose Maria Vieitez
SRS. García Rivas
S. García Rivas
JGJosé Luis Zamorano Gómez
José Luis Zamorano Gómez

1 August 2018 in European Heart Journal
Verified
Journal Article
Open access
PDF file
SJS Hernandez Jimenez
S Hernandez Jimenez
RBR Hinojar Baydes
R Hinojar Baydes
AGA Gonzalez-Gomez
A Gonzalez-Gomez
AEA Esteban-Peris
A Esteban-Peris
MFM A Fernandez-Mendez
M A Fernandez-Mendez
CGCovadonga Fernández Golfín
Covadonga Fernández Golfín
Introduction: Right ventricular (RV) systolic function is an important predictor of prognosis in several cardiovascular conditions. RV ejection fraction (RVEF) by cardiovascular magnetic resonance (CMR) is the gold standard of RV systolic function in tricuspid regurgitation (TR); however, it can be deteriorated late in the course of the disease.